[CAS NO. 444731-52-6] Pazopanib

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [444731-52-6]

Catalog

SLK-S3012

Brand

Selleck

CAS

444731-52-6

DESCRIPTION [444731-52-6]

Overview

MDL	MFCD11616589
Molecular Weight	437.52
Molecular Formula	C21H23N7O2S
SMILES	CC1=C2C(C=C(N(C)C3=NC(NC4=CC(S(N)(=O)=O)=C(C)C=C4)=NC=C3)C=C2)=NN1C

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Description

Pazopanib (GW786034) is a novel multi-target inhibitor of , , , PDGFR, FGFR, c-Kit and c-Fms/CSF1R with of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively. Pazopanib induces activation and .

Targets

In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. PPazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability.

References

[1] Harris PA, et al. J Med Chem. 2008, 51(15), 4632-4640.
[2] Hosaka S, et al. J Orthop Res. 2012.
[3] Kernt M, et al. Retina. 2012.

Synonyms

Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-

5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide

Pazopanib

5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide

GW 786034

Votrient

AE 941